LEE'S PHARM (00950) Receives NMPA Approval for Inrosa

Stock News

03/25

It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1163342752"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1163342752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1163342752?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-25 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163342752","market":"sh","top_or_hot":-1,"title":"LEE'S PHARM (00950) Receives NMPA Approval for Inrosa","media":"Stock News","content":"<p>It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEE'S PHARM (00950) Receives NMPA Approval for Inrosa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEE'S PHARM (00950) Receives NMPA Approval for Inrosa\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-25 21:38</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06622","symbol_name":"兆科眼科-B","start_time":0,"source_url":"","article_id":"1163342752","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163342752","pubTimestamp":1774445903,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06622":"兆科眼科-B","BK1583":"高瓴概念","BK1191":"制药","BK1574":"生物医药B类股","BK1587":"次新股","00950":"李氏大药厂"},"translate_title":"李氏药业(00950)Inrosa获NMPA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1,"00950":1},"content_text":"It was announced that LEE'S PHARM (00950) has obtained approval from China's National Medical Products Administration (NMPA) for Inrosa on March 17, 2026. Inrosa, which is owned by Cosette Pharmaceuticals and has been licensed to LEE'S PHARM, is indicated for the treatment of vulvovaginal atrophy in postmenopausal women with moderate to severe symptoms, excluding urological symptoms. This approval represents a significant milestone following the successful completion of a Phase III, multicenter, randomized, double-blind, parallel-controlled clinical trial conducted by the company's wholly-owned subsidiary, Zhaoke Pharmaceutical (Hefei) Co., Ltd.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}